Direct Flow makes ex-CoreValve CEO new chief
This article was originally published in Clinica
Transcatheter aortic valve implantation (TAVI) specialist Direct Flow Medical has signalled its intent to compete with the likes of Medtronic and Edwards Lifesciences by appointing a new heavyweight CEO. Daniel Lemaitre was previously in charge at CoreValve, which was acquired by Medtronic for $800m; before that, he led strategic planning and business development for Medtronic. Mr Lemaitre replaces Bernard Lyons, who will be retiring. Direct Flow also named David Boyle as CFO – he has held the position at five healthcare companies including, most recently, drug developer Ogenx Therapeutics. Direct Flow has developed a CE-marked repositionable and retrievable valve that it claims completely eliminates aortic regurgitation, a complication seen with older products. It is currently carrying out a pivotal study in the US, SALUS, and has previously said it hopes for FDA approval in the first half of 2017.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.